China Tightens Regulations on Oxycodone

August 8, 2019

China’s National Medical Products Administration announced that it is placing new restrictions on oxycodone.

The drug regulator said some formulations of the controversial opioid pain medication will be classified as psychotropic drugs and will have to go through additional approval steps to be manufactured or prescribed.

Beginning Sept. 1, oral solid formulations containing more than 5 mg of oxycodone per unit will be regulated as first-class psychotropic drugs, the agency said.

View today's stories